Výsledky vyhledávání

Publikováno v: AJN, American Journal of Nursing. 116:36-45

More than 12% of women will be diagnosed with breast cancer at some point in their lives, and 78% of them can be expected to survive for at least 15 years. More than 2.8 million breast cancer survivors currently reside in the United States. After bre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2ad7504a88ceb825f6b0d500dcef4fd
https://doi.org/10.1097/01.naj.0000484223.07306.45

Zobrazit plný text záznamu

The Role of Advanced Practice Nurses in Cancer Survivorship Care

Autor: Mary S. McCabe, Megan Dunne, Stacie Corcoran

Publikováno v: Seminars in Oncology Nursing. 31:338-347

Objectives To review advanced practice nursing roles in planning, implementing, and evaluating survivorship care. Data Sources Review of the literature, published articles, government and organizational reports. Conclusion The increased focus on impr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e547a88fa26d90375e923695caff0df3
https://doi.org/10.1016/j.soncn.2015.08.009

Zobrazit plný text záznamu

A Phase II Tolerability Study of Cisplatin Plus Docetaxel as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer

Autor: Lee M. Krug, Barbara Coleman, Barbara Pizzo, Lauren Lastinger, Teresa Seeger, Christopher G. Azzoli, Amy Farmer, Charles M. Rudin, Mark G. Kris, Erin Moore, Naiyer A. Rizvi, Vincent A. Miller, Leslie B. Tyson, Ennapadam Venkatraman, Megan Dunne

Publikováno v: Journal of Thoracic Oncology. 2(7):638-644

Introduction We undertook this phase II study to measure postoperative drug delivery and toxicity of cisplatin plus docetaxel in patients with resected stage I-III non-small cell lung cancer. Methods The primary endpoint was amount of cisplatin deliv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::891e53ed38a5ccd86ac88ba9a6be5ea6

Zobrazit plný text záznamu

Differential Effects of Two Spelling Procedures on Acquisition, Maintenance and Adaption to Reading

Autor: Jennifer Wierzbicki, Gary L. Cates, Nicole Lee, Megan Dunne, Aaron J. Kivisto, Karyn N. Erkfritz

Publikováno v: Journal of Behavioral Education. 16:70-81

An alternating treatments design was used to assess the effects of a constant time delay (CTD) procedure and a cover-copy-compare (CCC) procedure on three students’ acquisition, subsequent maintenance, and adaptation (i.e., application) of acquired

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::36d91eff3f17ef8753a1d6c97993a30e
https://doi.org/10.1007/s10864-006-9019-5

Zobrazit plný text záznamu

A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors

Autor: Barbara Pizzo, Jorge Gomez, Michelle S. Ginsberg, Lee M. Krug, Christopher G. Azzoli, Frank Sirotnak, Leslie B. Tyson, Roxanne Henry, Robert Steffen, Mark G. Kris, Megan Dunne, Vincent A. Miller, Ennapadam Venkatraman, Jessica Jones, Amy Farmer

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 13(9)

Purpose: Pralatrexate is a rationally designed antifolate with greater preclinical antitumor activity than methotrexate. Pralatrexate was synergistic with paclitaxel and with docetaxel in mouse xenograft experiments. This phase 1 study was designed t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::221367703f8da75bbbb5ee93555a0998
https://pubmed.ncbi.nlm.nih.gov/17473201

Zobrazit plný text záznamu

A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer

Autor: Lee M. Krug, Robert T. Heelan, Mark G. Kris, Christopher G. Azzoli, Naiyer A. Rizvi, Daniel T. Milton, William Pao, Megan Dunne, Vincent A. Miller, Ennapadam Venkatraman, Jorge Gomez

Publikováno v: Cancer. 107(5)

BACKGROUND. Preclinical studies have suggested that erlotinib at high doses may inhibit additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in greater antitumor efficacy. The objective of this study was to determine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8260065870b42b8dc15d7c7cec4b5c9f
https://pubmed.ncbi.nlm.nih.gov/16878326

Zobrazit plný text záznamu

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial

Autor: Megan Dunne, Christopher G. Azzoli, Robert T. Heelan, Barbara Pizzo, Vincent A. Miller, Lee M. Krug, Naiyer A. Rizvi, Mark G. Kris, John P. Crapanzano, Jorge Gomez, Leslie B. Tyson

Publikováno v: Cancer. 103(10)

BACKGROUND Imatinib inhibits the c-kit tyrosine kinase, which, accounts for its activity in gastrointestinal stromal tumors. The presence of c-kit protein expression in small cell lung carcinoma (SCLC) tumor specimens, as well as in vitro data suppor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::019204c57dfbc01324017563dd0d9be6
https://pubmed.ncbi.nlm.nih.gov/16161057

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání